A Mutated Prostatic Acid Phosphatase (PAP) Peptide-Based Vaccine Induces PAP-Specific CD8⁺ T Cells with Ex Vivo Cytotoxic Capacities in HHDII/DR1 Transgenic Mice.

ABSTRACT:

Background

Current treatments for castrate (hormone)-resistant prostate cancer (CRPC) remain limited and are not curative, with a median survival from diagnosis of 23 months. The PAP-specific Sipuleucel-T vaccine, which was approved by the FDA in 2010, increases the Overall Survival (OS) by 4 months, but is extremely expensive. We have previously shown that a 15 amino accid (AA) PAP sequence-derived peptide could induce strong immune responses and delay the growth of murine TRAMP-C1 prostate tumors. We have now substituted one amino acid and elongated the sequence to include epitopes predicted to bind to several additional HLA haplotypes. Herein, we present the immunological properties of this 42mer-mutated PAP-derived sequence (MutPAP42mer).

Methods

The presence of PAP-135-

SUBMITTER: Vu PL 

PROVIDER: S-EPMC9032647 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature